 |
 |
SCDMDG presents:
Human Microbiome and Metabolome Dynamics
Tuesday May 30, 2017
Rob Knight, Ph.D.
Founding Director, Center for Microbiome Innovation,
Jacobs School of Engineering with the School of Medicine
Professor, Department of Pediatrics
Professor, Department of Computer Science
University of California San Diego
 (photo credit David Ahntholz)
About The Meeting
Advances in technology allow us to understand the human microbiota not as a static entity but as a complex, changing ecosystem that records substantial data about our lifestyles, our environmental exposures, and the people we live with. Here I discuss changes in the human microbiota associated with early life events such as delivery mode and antibiotics, the subsequent development of the microbiome throughout life, and even the development of the microbiome after death and its potential utility for forensics. Of particular value for toxicological studies is the ability to transfer the microbiome to germ-free mice, allowing individualized tests of function and subsequent therapies to be tested in personalized rodent models. Relating human to rodent microbiome timescales, especially for dietary studies, and relating multi-omics data in a timeseries context, remain outstanding challenges. Rapid progress is being made in these areas, and will allow far more powerful studies of the effects of drugs in mammalian hosts and our ability to stratify responders from non-responders for a wide range of therapies.
Space is Limited — Register Early to Guarantee Your Attendance!
Click here for a printable flyer.
Our Spring 2017 meeting is generously sponsored by:
Silver Sponsors
Bronze Sponsors

National University
For more information on sponsoring our May meeting, please refer to our sponsorship guidelines.
Prior presentations:
Note: slides are displayed in a new window, left-click to advance, right-click to go back.
Speaker |
PDF |
Topic |
Date |
Kim L. R. Brouwer, Pharm.D., Ph.D. |
|
Altered Disposition of Drugs and Bile Acids in Patients with Non-Alcoholic Steatohepatitis (NASH) |
December 7, 2016 |
Les Benet, Ph.D. |
 |
The Use of BDDCS in Drug Development: The Observations, The Predictions, Understanding the Scientific Basis and The Extensions |
April 19, 2016 |
Nicholas J. Schork, Ph.D. |
|
Design and Implementation Issues in Clinical Trials Advancing Personalized Medicine |
September 15, 2015 |
Robert P. Hanzlik, Ph.D. |
|
Reactive Metabolites, Cellular Targets and Beyond |
April 28, 2015 |
J. Ernest Simpson, Ph.D. |
|
The Chemistry Of Wine |
October 28, 2014 |
Lawrence J. Marnett, Ph.D., F.C.P |
|
Next Generation NSAIDs That Selectively Inhibit Endocannabinoid Metabolism by COX-2 |
May 6, 2014 |
Lawrence J. Lesko, Ph.D., F.C.P. |
 |
Drug Interaction Studies: Differences and Similarities in How to Meet the Regulatory Expectations in FDA Guidance and EMA Guidelines |
May 14, 2013 |
Thomas Tozer, Ph.D. |

 |
Pharmacokinetics of Protein Drugs |
October 23, 2012 |
Shujuan Chen |
 |
Application of Animal Models for Human Glucuronidation |
October 23, 2012 |
Caroline Decker |
| The Use of Modified Bacterial CYPs for Metabolite Generation |
October 23, 2012 |
Mary Dwyer, Ph.D. |
| Cancer Therapeutics: A Novel Approach |
October 23, 2012 |
Justin Hoffman PharmD MS |
| Population Pharmacokinetics (PK) of LopinavirDuring Pregnancy and Postpartum |
October 23, 2012 |
David A. Yee |
| Observations on the Urine Metabolic Ratio of Oxymorphone to Oxycodone in Pain Patients |
October 23, 2012 |
Nabil Hanna, Ph.D. |
|
The Discovery and Development of Rituxan |
April 10, 2012 |
Dr. Richard Kim |
 |
Drug Transporters: In Vitro and Knockout Model Systems, Pharmacogenomics, and Clinical Relevance |
April 19, 2011 |
Dr. Jerry Galluppi |
 |
Biotherapeutic Drug Research and Development: A Growing Role for the DMPK Scientist |
October 5, 2010 |
Dr. Dennis Smith |
 |
Does drug metabolism hold its future in its own hands? |
April 27, 2010 |
Dr. Paul F. Hollenberg |
 |
Mechanism-Based Inactivation of Human Cytochromes P450 |
October 6, 2009 |
Dr. Jack H. Dean Dr. Thomas Baillie |
|
Challenges & Opportunities in Drug Development from a Drug Safety and Metabolism Perspective |
May 19, 2009 |
Eric Johnson, Ph.D. |
|
Characterization of Substrate/Inhibitor Binding to Drug-Metabolizing Cytochrome P450 Monooxygenases using X-ray Crystallography |
September 30, 2008 |
Dr. Kenneth E. Thummel, Ph.D. |
|
Regulation Of Intestinal CYP3A By VDR: Implications And Safety Of Oral Therapeutics |
May 7, 2008 |
Dr. Anthony Lu, Ph.D. |
|
Why Is The Liver Microsomal Cytochrome P450 Such A Versatile And Unique Enzyme? |
September 12, 2007 |
Dr. Scott Obach, Ph.D. |
|
Leveraging ADME Data In Metabolites In Safety Testing (MIST) |
April 18, 2007 |
Dr. Sidney Nelson, Ph.D. |
|
Drug Metabolism and Chemical Structural Alerts |
September 27, 2006 |
Richard B. Kim, MD |
|
Relevance and Utility of Transporters to Drug Discovery and Development |
September 21, 2005 |
Dr. Frederick P. Guengerich, Ph.D. |
|
Human Cytochrome P450 2A6 as a Case History: Flavors, Smoke, Blue Roses, New Drugs & Basics of a P450 |
April 27, 2005 |
Dr. Leslie Benet, Ph.D. |
|
Predicting Drug Disposition via Application of BCS: Transport/Absorption/Elimination Interplay and BDDCS |
September 29, 2004 |
Dr. Christopher A. Lipinski, Ph.D. |
|
ADME/Tox: How Low Can You Go And How Do You Recover? |
April 21, 2004 |
|
 |
 |